Viral hepatitis A and B are one of the most spread diseases among children and grown-ups in Russia. Mixed hepatitis forms (both A and B) are often registered nowadays. Facing this challenge, SRC VB VECTOR and Production Unit "Vector-BiAlgam" started developing mixed divalent vaccine "Hep A+B-in-VAC" in 1998.
Viral hepatitis A and B are one of the most spread diseases among children and grown-ups in Russia. Mixed hepatitis forms (both A and B) are often registered nowadays.
Facing this challenge, SRC VB VECTOR and Production Unit "Vector-BiAlgam" started developing mixed divalent vaccine "Hep A+B-in-VAC" in 1998.
Vaccine prophylaxis of viral hepatitis A and B is an efficient method of morbidity reduction. Single-step introduction of existing commercial vaccines against hepatitis A and B is regulated by order of Ministry of Public Health of Russian Federation. However, two-time introduction of vaccine against hepatitis A and three-time introduction against hepatitis B represent an essential inconvenience for public health practice. Mixed divalent vaccine allows not only creating protection against two infections, but at the same time shortening injections' amount twice.
At the present time the drug is at the registration at the L.A.Tarasevich State Institute of Standardization and Control. According to specialists' forecast, the first pilot vaccine series appear in 2006.